ArticleCellular oncology (Dordrecht, Netherlands)2015
Anti-proliferative, apoptotic and signal transduction effects of hesperidin in non-small cell lung cancer cells.
Article in Cellular oncology (Dordrecht, Netherlands), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 92 citations in OpenAlex.
- Agro-Industrial Plant Biomass as a Sustainable Source of Anticancer Polyphenols: Molecular Mechanisms and Future Perspectives.Current issues in molecular biology · 2026Review
- Programmed cell death in lung cancer: mechanisms, immune responses, and therapeutics.Apoptosis : an international journal on programmed cell death · 2026Review
- Phytochemical-Based Strategies for Lung Cancer: Clinical Insights Into Pleiotropic Molecular Signaling and Therapeutic Roles.Phytotherapy research : PTR · 2026Review
- Orchestration of the tumor microenvironment by citrus flavonoids: from preclinical mechanisms to translational therapeutic.Frontiers in immunology · 2026Review
- Synergistic Anticancer Effects of Bleomycin and Hesperidin Combination on A549 Non-Small Cell Lung Cancer Cells: Antiproliferative, Apoptotic, Anti-Angiogenic, and Autophagic Insights.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Hesperidin Improves Wound Healing and Mineralization of Periodontal Ligament Cells in Elevated Glucose Conditions.Current medicinal chemistry · 2025Article
- Medicinal plants as a potential resource for the discovery of novel structures towards cancer drug resistance treatment.Heliyon · 2024Review
- MicroRNAs and the Mediterranean diet: a nutri-omics perspective for lung cancer.Journal of translational medicine · 2024Review
- Hesperidin ameliorates HJournal of animal science and biotechnology · 2024Article
- Exploring the Anticancer Potential of Traditional Thai Medicinal Plants: A Focus onPlants (Basel, Switzerland) · 2024Article
- The antitumour efficacy of hesperidin vs. cisplatin against non-small lung cancer cells A549 and H460Contemporary oncology (Poznan, Poland) · 2024Article
- Review
- Hesperidin, a Bioflavonoid in Cancer Therapy: A Review for a Mechanism of Action through the Modulation of Cell Signaling Pathways.Molecules (Basel, Switzerland) · 2023Review
- A Scientometric Study to a Critical Review on Promising Anticancer and Neuroprotective Compounds: Citrus Flavonoids.Antioxidants (Basel, Switzerland) · 2023Review
- Role of Plant-Derived Active Constituents in Cancer Treatment and Their Mechanisms of Action.Cells · 2022Review
- Hesperidin Inhibits Lung CancerFrontiers in pharmacology · 2022Article
- Article
- Therapeutic Effects and Molecular Mechanisms of Bioactive Compounds Against Respiratory Diseases: Traditional Chinese Medicine Theory and High-Frequency Use.Frontiers in pharmacology · 2021Review
- Potential Application of Plant-Based Functional Foods in the Development of Immune Boosters.Frontiers in pharmacology · 2021Review
- Hesperidin administration suppresses the proliferation of lung cancer cells by promoting apoptosis via targeting the miR‑132/ZEB2 signalling pathway.International journal of molecular medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHesperidin, a glycoside flavonoid, is thought to act as an anti-cancer agent, since it has been found to exhibit both pro-apoptotic and anti-proliferative effects in several cancer cell types. The mechanisms underlying hesperidin-induced growth arrest and apoptosis are, however, not well understood. Here, we aimed to investigate the anti-proliferative and apoptotic effects of hesperidin on non-small cell lung cancer (NSCLC) cells and to investigate the mechanisms involved.
methodsThe anti-proliferative and apoptotic effects of hesperidin on two NSCLC-derived cell lines, A549 and NCI-H358, were determined using a WST-1 colorimetric assay, a LDH cytotoxicity assay, a Cell Death Detection assay, an AnnexinV-FITC assay, a caspase-3 assay and a JC-1 assay, respectively, all in a time- and dose-dependent manner. As a control, non-cancerous MRC-5 lung fibroblasts were included. Changes in whole genome gene expression profiles were assessed using an Illumina Human HT-12v4 beadchip microarray platform, and subsequent data analyses were performed using an Illumina Genome Studio and Ingenuity Pathway Analyser (IPA).
resultsWe found that after hesperidin treatment, A549 and NCI-H358 cells exhibited decreasing cell proliferation and increasing caspase-3 and other apoptosis-related activities, in conjunction with decreasing mitochondrial membrane potential activities, in a dose- and time-dependent manner. Through a GO analysis, by which changes in gene expression profiles were compared, we found that the FGF and NF-κB signal transduction pathways were most significantly affected in the hesperidin treated NCI-H358 and A549 NSCLC cells.
conclusionsOur results indicate that hesperidin elicits an in vitro growth inhibitory effect on NSCLC cells by modulating immune response-related pathways that affect apoptosis. When confirmed in vivo, hesperidin may serve as a novel anti-proliferative agent for non-small cell lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.